STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 29, 2016	$ 131,449	$ 117,036,345	$ (117,268,812)	$ (101,018)
Balance (in shares) at Feb. 29, 2016	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		311,943		311,943
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		1,260,791		1,260,791
Net loss			(1,504,717)	(1,504,717)
Balance at Feb. 28, 2017	$ 131,449	118,609,079	(118,773,529)	(33,001)
Balance (in shares) at Feb. 28, 2017	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		319,268		319,268
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		1,218,134		1,218,134
Net loss			(1,612,101)	(1,612,101)
Balance at Feb. 28, 2018	$ 131,449	$ 120,146,481	$ (120,385,630)	$ (107,700)
Balance (in shares) at Feb. 28, 2018	131,448,444